hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06283524 id: ETNA-TrainMS briefTitle: Eye-tracking Investigation of Clinical Measures in Multiple Sclerosis overallStatus: NOT_YET_RECRUITING date: 2024-03-18 date: 2025-10-18 date: 2026-03-18 date: 2024-02-28 date: 2024-02-28 name: Innodem Neurosciences class: INDUSTRY briefSummary: The overarching goal of this research protocol is to acquire eye-tracking, cognitive, and disease-severity metrics in MS patients to train machine learning algorithms that will support the development and performance assessment of a sensitive and non-invasive eye-tracking software application. The training of our machine learning classifying algorithms to identify which eye-tracking metrics-or combination thereof-can serve as reliable markers of MS disease severity and cognitive status. conditions: Multiple Sclerosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 100 type: ESTIMATED name: Eye-Tracking measure: Predictive power of eye-movement biomarkers (EMBs) for MS severity in relationship to Expanded Disability Status Scale (EDSS) measure: Predictive power of eye-movement biomarkers (EMBs) for cognitive status in relationship to the Symbol Digit Modalities Test (SDMT) as part of the Brief International Cognitive Assessment for MS (BICAMS). measure: Predictive power of eye-movement biomarkers (EMBs) for cognitive status in relationship to the Rey Auditory Verbal Learning Test (RAVLT) as part of the Brief International Cognitive Assessment for MS (BICAMS). measure: Predictive power of eye-movement biomarkers (EMBs) for cognitive status in relationship to the Brief Visuospatial Memory Test-Revised (BVMT-R) as part of the Brief International Cognitive Assessment for MS (BICAMS). measure: Predictive power of eye-movement biomarkers (EMBs) for physical disability in relationship to the Timed 25-foot walk as part of the Multiple sclerosis functional composite (MSFC). measure: Predictive power of eye-movement biomarkers (EMBs) for physical disability in relationship to the 9-Hole Peg Test (9-HPT) as part of the Multiple sclerosis functional composite (MSFC). sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Genge Partners, Inc. city: Montréal state: Quebec zip: H4A 3T4 country: Canada name: Yousri Benchaar role: CONTACT phone: 514-906-3876 phoneExt: 6026 email: YBenchaar@gengepartners.com name: Alexander Saveriano, MD role: PRINCIPAL_INVESTIGATOR lat: 45.50884 lon: -73.58781 hasResults: False
nctId: NCT06283511 id: IJB-RESTART briefTitle: Evaluation of the RESTART Survival Programme overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2025-08 date: 2026-12 date: 2024-02-28 date: 2024-02-28 name: Jules Bordet Institute class: OTHER briefSummary: The RESTART survivorship programme has been implemented in the care pathway for patients with localised breast cancer since 2022. In this project, investigators are going to evaluate the satisfaction of patients taking part in the RESTART programme, as well as measuring changes in quality of life and health literacy after participation in the RESTART programme. conditions: Invasive Breast Cancer studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 200 type: ESTIMATED name: educational workshops measure: Assessment of satisfaction with participation in the Restart programme and its various components via Likert scale and open questions. measure: assessment of quality of life measure: assessemnt of health literacy via HLQ questionnaire measure: assessment of professional status measure: assessment of level of physical activity measure: assessment of emotionnal distress measure: assessment of the intensity of residual fatigue measure: assessment of sleep quality measure: Measuring the rate of participation in the programme measure: assessment of quality of life measure: assessment of emotionnal distress sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06283498 id: DO612574A briefTitle: Transvaginal Detrusor Nerve Radiofrequency Ablation for Treatment of Overactive Bladder overallStatus: ENROLLING_BY_INVITATION date: 2023-11-10 date: 2025-11 date: 2026-07 date: 2024-02-28 date: 2024-03-01 name: InMode MD Ltd. class: INDUSTRY briefSummary: The goal of this Safety and efficacy of transvaginal Detrusor Nerve Ablation for treatment of overactive bladder symptoms, including refractory overactive bladder
Follow-up will occur at 3- months, 6-months and 12 months after the subject's last treatment. conditions: Overactive Bladder Syndrome studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Device Morpheus8V measure: Change in urgency incontinence episodes after 3 month measure: Change in urgency incontinence episodes after 1 month measure: Change in urgency incontinence episodes measure: Change in urgency incontinence episodes measure: Analysis to assess the urinary frequency measure: Analysis to assess urinary frequency measure: Analysis to assess the urinary frequency. measure: Analysis to assess the urinary frequency. measure: Assessment of the impact of the treatment on Overactive Bladder symptoms measure: Assessment of the impact of the treatment on Overactive Bladder symptoms measure: Assessment of the impact of the treatment on Overactive Bladder symptoms measure: Assessment of the impact of the treatment on Overactive Bladder symptoms measure: Patient-reported Pain assessment measure: Patient-reported outcome measure measure: Patient-reported outcome measure measure: Patient-reported outcome measure measure: Patient-reported outcome measure sex: FEMALE minimumAge: 21 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mickey Karram MD city: Corona Del Mar state: California zip: 92625 country: United States lat: 33.59808 lon: -117.87311 facility: Institute for Female Pelvic Medicine city: Knoxville state: Tennessee zip: 37932 country: United States lat: 35.96064 lon: -83.92074 hasResults: False
nctId: NCT06283485 id: Study Artificial intelligence briefTitle: Real-time Anatomy Recognition Tool Accuracy Research for Ultrasound-guided PENG and Suprainguinal Fascia Iliaca Blocks overallStatus: RECRUITING date: 2023-12-15 date: 2024-04-01 date: 2024-05-25 date: 2024-02-28 date: 2024-02-28 name: Konya City Hospital class: OTHER name: Betül Afşar briefSummary: Background and rationale: Ultrasound-guided regional anesthesia is a widely used pain control method today. A critical aspect of the procedure is accurate visualization of anatomical structures on ultrasound to precisely define target areas. Distinguishing surrounding tissues with an imaging model that automatically recognizes sonoanatomy in ultrasound images will reduce unintended intraneural injections or injury to other anatomical structures in close proximity and increase patient safety.
Hypothesis; Numerous studies have shown that the use of ultrasound and neurostimulators in practice increases the success, onset and quality of nerve blocks, but due to the low incidence of major complications and the absence of comparable randomized studies, no definitive statement can be made as to whether ultrasound reduces the overall rate of nerve damage. An imaging model that automatically marks sonoanatomy with artificial intelligence in ultrasound images can reduce unintended intraneural injections or injury to other anatomical structures in close proximity and improve patient safety. conditions: Artificial Intelligent conditions: Ultrasound Therapy; Complications conditions: Nerve Block studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 150 type: ESTIMATED name: ultrasound examination measure: Artificial intelligence Program size measure: Score of assessment the pictures sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Yasin Tire status: RECRUITING city: Konya state: Meram zip: 42140 country: Turkey name: Yasin Tire role: CONTACT phone: +905055367970 email: dryasintire@hotmail.com name: Betül Afşar role: CONTACT lat: 37.87135 lon: 32.48464 hasResults: False
nctId: NCT06283472 id: 1805574553; Aims 14-16 id: 2P60AA007611-403343 type: OTHER_GRANT domain: National Institute on Alcohol Abuse and Alcoholism id: 2P60AA007611 type: NIH link: https://reporter.nih.gov/quickSearch/2P60AA007611 briefTitle: Enhancing Prospective Thinking in Early Recovery (BEAM) acronym: BEAM overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2026-12-01 date: 2027-02-01 date: 2024-02-28 date: 2024-03-01 name: Indiana University class: OTHER briefSummary: The goal of this clinical trial is to test the prosocial effects of personally-relevant, high-intensity episodic future-thinking (EFT) cues in alcohol use disorder persons and related brain mechanisms. The main question\[s\] this trial aims to answer are:
Researchers will compare the experimental (high-intensity group) and control (low-intensity) groups to see if there are differences in the results for the questions outlined above. conditions: Alcohol Use Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: Eligible participants will be randomly assigned to either the high-intensity (experimental) or low-intensity (control) groups. whoMasked: PARTICIPANT count: 150 type: ESTIMATED name: High-Intensity Cue name: Low-Intensity Cue measure: Increase Prospective Thinking measure: Delayed Rewards sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06283459 id: 301-23-101 briefTitle: Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2 overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-09-30 date: 2025-09-30 date: 2024-02-28 date: 2024-04-05 name: Imunon class: INDUSTRY briefSummary: This is an open-label phase 1/2, dose-escalation study. Participants will receive a single intramuscular (IM) dose of IMNN-101 on Day 0 in the deltoid muscle and will be followed through 12 months post-vaccination (through Study Day 365). conditions: SARS CoV 2 Infection studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 74 type: ESTIMATED name: IMNN-101 measure: Number of participants with local and systemic reactogenicity adverse events and all adverse events measure: Number of participants with geometric mean titer (GMT) of the serum neutralizing antibody (Nab) against the Omicron XBB.1.5 strain. measure: Number of participants with GMT of serum spike binding IgG antibodies measure: Number of participants with a magnitude and phenotype of cytokine producing S protein-specific T cells, as measured by flow cytometry and/or ELISpot. measure: Number of participants with seroresponse rate (SRR). sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beth Israel Deaconess Medical Center city: Boston state: Massachusetts zip: 02215 country: United States name: Elizabeth Oginni role: CONTACT email: ooginni@bidmc.harvard.edu name: Ai-Ris Y Collier, MD role: PRINCIPAL_INVESTIGATOR lat: 42.35843 lon: -71.05977 facility: DM Clinical Research city: Philadelphia state: Pennsylvania zip: 19107 country: United States name: Kyle Bramble role: CONTACT email: kyle.bramble@dmclinical.com name: Kem Yenal, MD role: PRINCIPAL_INVESTIGATOR lat: 39.95233 lon: -75.16379 hasResults: False
nctId: NCT06283446 id: 1805574553; Aims 11-13 id: 1R21AA029760-01 type: NIH link: https://reporter.nih.gov/quickSearch/1R21AA029760-01 briefTitle: Enhancing Prospective Thinking in Early Recovery acronym: NERF overallStatus: RECRUITING date: 2023-12-20 date: 2024-07-31 date: 2024-07-31 date: 2024-02-28 date: 2024-02-28 name: Indiana University class: OTHER name: National Institute on Alcohol Abuse and Alcoholism (NIAAA) briefSummary: The goal of this clinical trial is to test the prosocial effects of personally-relevant, high-intensity episodic future-thinking (EFT) cues in alcohol use disorder persons and related brain mechanisms. The main question\[s\] this trial aims to answer are:
Will high-intensity EFT cues will produce greater delayed reward preference than low-intensity cues? Will high-intensity EFT cues effect greater treatment-seeking interest? Will high-intensity EFT cues elicit greater response in regions for prospective thinking during delay discounting (vs. low-intensity) Will nucleus accumbens-precuneus resting connectivity correlate with behavioral SS? Will the novel behavioral SS decision-making task activate the nucleus accumbens? Researchers will compare the experimental (high-intensity group) and control (low-intensity) groups to see if there are differences in the results for the questions outlined above. conditions: Alcohol Use Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: SINGLE maskingDescription: Eligible participants will be randomly assigned to either the high-intensity (experimental) or low-intensity (control) groups. whoMasked: PARTICIPANT count: 98 type: ESTIMATED name: High-Intensity Cue name: Low-Intensity Cue measure: Increase Prospective Thinking measure: Delayed Rewards sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Indiana University School of Medicine - Goodman Hall status: RECRUITING city: Indianapolis state: Indiana zip: 46202 country: United States name: Sarah Turo, BA role: CONTACT phone: 317-963-7220 email: sturo@iu.edu name: Colton Lind, BS role: CONTACT phone: 317-963-2554 email: cmlind@iu.edu name: Brandon G Oberlin, PhD role: PRINCIPAL_INVESTIGATOR lat: 39.76838 lon: -86.15804 hasResults: False
nctId: NCT06283433 id: NL83813.078.23 briefTitle: A Dried Blood Spot Sampling Method for Vancomycin and Creatinine Monitoring for OPAT acronym: ADVANCEDOPAT overallStatus: RECRUITING date: 2023-10-25 date: 2024-11 date: 2024-11 date: 2024-02-28 date: 2024-02-28 name: Erasmus Medical Center class: OTHER briefSummary: The Outpatient Parenteral Antibiotic Therapy (OPAT) service consists of providing antimicrobial therapy through parenteral infusion without hospitalization. This service is provided to stable patients otherwise ready for hospital discharge. Generally, the clinical monitoring for this patient population is minimal. However, clinical monitoring of vancomycin, an antibiotic widely used during OPAT, can be intensive primarily due to therapeutic drug monitoring. To ensure optimal treatment and minimize nephrotoxicity and microbial resistance, TDM and monitoring of serum creatinine levels are crucial during vancomycin therapy. TDM of vancomycin with OPAT presents a challenge for patients who must frequently travel to blood sampling facilities or the hospital for measurements. An alternative sampling method for TDM is the dried blood spot (DBS) method, which involves collecting a small drop of capillary blood from a finger prick onto filter paper. By implementing the DBS sampling method, the amount of outpatient visits regarding vancomycin treatment in OPAT can be reduced. Furthermore, the addition of measuring a biochemical parameter, such as renal function with serum creatinine, could lead to even less outpatient visits during OPAT. To date, studies investigating the effectiveness of DBS sampling of vancomycin and creatinine in terms of reducing outpatient visits have not yet been conducted in the OPAT population. conditions: Infection, Bacterial studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 84 type: ESTIMATED name: Finger Prick name: Venipuncture measure: To compare the number of outpatient visits in the control group versus the intervention group at day 28 measure: Outcomes regarding outpatient visit measure: Sampling outcomes measure: Satisfaction with blood sampling based on the theoretical framework of acceptability questionnaire (TFA) measure: Cost outcomes measure: Clinical outcomes measure: TDM outcomes measure: Logistical outcomes sex: ALL minimumAge: 18 Years maximumAge: 120 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Erasmus MC status: RECRUITING city: Rotterdam country: Netherlands name: Birgit Koch, PharmD role: CONTACT lat: 51.9225 lon: 4.47917 hasResults: False
nctId: NCT06283420 id: CarDia_WP5_P1_IRB:25059/23 briefTitle: Metabolic Response to Iniciation of Heart Failure Therapy acronym: GliF overallStatus: NOT_YET_RECRUITING date: 2024-02-21 date: 2025-12-20 date: 2026-12-20 date: 2024-02-28 date: 2024-02-28 name: Vojtech Melenovsky, MD, PhD class: OTHER_GOV briefSummary: This protocol is part of the CarDia project - National Institute for Metabolic and Cardiovascular Disease Research (EXCELES Program, ID: LX22NPO5104), funded by the European Union - Next Generation EU. The protocol is part of Work Package 5 (WP5): metabolic disorders in heart failure.
The protocol will examine how parameters reflecting neurohumoral activation, response to hypoxia, systemic metabolism of energy substrates, parameters of iron metabolism, HIF1A activation in peripheral blood behave over time after starting standard heart failure terapiy (baseline, 1 day, 1 week, 1 month, 3 month). This project can provide valuable information on how to identify people who respond more poorly to the treatment being introduced and are more at risk of an adverse course of the disease. Patients will be compared to patients who have no change of therapy over early observation period (3 mo), who will serve as controls. This is observational study, so decision to inicialize therapy will be based on medical indication.
Patients with heart failure treated at the IKEM Cardiocenter will have blood drawn at several defined intervals before and after the start of clinically indicated treatment. Some patients will also undergo genetic DNA testing to determine the variability of genes regulating the metabolic neurohumoral response to heart failure. Patients will be contacted at intervals of 1 and 2 years and the incidence of clinical events will be monitored. The study is observational in nature and inclusion in the study does not affect the course of care provided or the choice of pharmacotherapy. conditions: Heart Failure studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 120 type: ESTIMATED measure: hematocrit measure: HIF response measure: hepcidin sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Institute for Clinical end Experimental Medicine - IKEM city: Prague country: Czechia lat: 50.08804 lon: 14.42076 hasResults: False
nctId: NCT06283407 id: ICF briefTitle: ICF-based Comparison on Musculoskeletal Health in Poland and Spain overallStatus: NOT_YET_RECRUITING date: 2024-03-04 date: 2024-06-03 date: 2024-11-04 date: 2024-02-28 date: 2024-03-01 name: University of Rzeszow class: OTHER name: Sanidad de Castilla y León briefSummary: Musculoskeletal conditions are a major cause of disability worldwide. These conditions are often associated with chronicity, which is a challenge for healthcare systems to address. Health care must be person-centred and take into account the individual perspective from which the disease is experienced. The lived experience of health conditions depends to a large extent on contextual factors. Comparison between different contexts helps to identify which aspects are most relevant in the experience of the disease. The International Classification of Functioning, Disability and Health (ICF) provides a unified language that allows such comparisons to be made. The aim of this study is to identify differences in musculoskeletal health between the Polish and Spanish populations using the ICF as a frame of reference. conditions: Musculoskeletal Diseases or Conditions studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 800 type: ESTIMATED name: ICF-based cross-country comparative analysis measure: Brief International Classification of Functioning, Disability and Health (ICF) core set for post-acute musculoskeletal conditions measure: Sociodemographic data of the sample (nationality, age, sex, education level, work status, number of comorbidities) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Rzeszow city: Rzeszów zip: 35-959 country: Poland name: Agnieszka Wiśniowska-Szurlej role: CONTACT lat: 50.04132 lon: 21.99901 hasResults: False
nctId: NCT06283394 id: 854803 briefTitle: AHA (American Heart Association) Food is Medicine Test of Choice Architecture and Salience of Incentives overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2025-05-15 date: 2025-06-01 date: 2024-02-28 date: 2024-04-19 name: University of Pennsylvania class: OTHER briefSummary: The goal of this interventional study is to test ways to improve the effectiveness of a healthy foods prescription program in increasing the purchase of healthy foods for patients who have both obesity (BMI \> 30) and diabetes (last A1C\>8 in the last 90 days). The main questions it aims to answer are:
Intervention Arms: The four treatment groups will also each receive a $160 subsidy per month for 3 months to be used on produce (fruits and vegetables). conditions: Obesity conditions: Diabetes studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 180 type: ESTIMATED name: Storefront Choice Architecture name: Fresh Funds name: Loss Framing measure: The primary outcome will be the percentage of food purchasing expenditures spent on eligible healthy foods. measure: Percentage of the $160 subsidy used each month in the intervention arms. measure: Change in hemoglobin A1c measure: Qualitative results sex: ALL minimumAge: 30 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06283381 id: 4264 briefTitle: The ESG Integrity Study: Effect of Proton Pump Inhibitors on the Structural Integrity of Endoscopic Sleeve Gastroplasty acronym: ESGIS overallStatus: RECRUITING date: 2024-02-01 date: 2025-01-31 date: 2026-06-30 date: 2024-02-28 date: 2024-02-28 name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS class: OTHER briefSummary: The study is a single center randomized, open-label, phase IV clinical trial. Obese patients who have indication to Endoscopic sleeve gastroplasty (ESG) for clinical reasons are included and ESG is performed as per clinical practice. After randomization, the patients are divided in two arms:
The primary aim of the study is to evaluate the effect of PPI on the structural integrity of the ESG conditions: Obesity studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Esomeprazole measure: The structural integrity of the sutures after Endoscopic sleeve gastroplasty (ESG) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione Policlinico Universitario A. Gemelli IRCCS status: RECRUITING city: Roma zip: 00168 country: Italy name: IVO BOSKOSKI role: CONTACT phone: +390630155701 email: ivo.boskoski@policlinicogemelli.it name: IVO BOSKOSKI role: PRINCIPAL_INVESTIGATOR lat: 41.89193 lon: 12.51133 hasResults: False